001060 KSC Week ended 07 Aug 2026

Weekly Investor Report

JW Pharmaceutical Corporation · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 24,900 KRW
6.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -14.9% below the Trend Line and sits at 25.5% of its 52-week range. The latest completed week returned 6.0%, after a -0.4% four-week move. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.

Setup score 28 out of 100
Latest Close 24,900 KRW 7 Aug 2026
1W Return 6.0% latest completed week
4W Return -0.4% short-term follow-through
12W Return -17.0% quarterly tape
Trend Breadth 53.8% 28 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.0% Latest completed week; four-week move -0.4%. Indicator stack 30/26 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 50/100 4 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -14.9% below the Trend Line and sits at 25.5% of its 52-week range. The latest completed week returned 6.0%, after a -0.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2312-week average 0.47

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.23Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.4% over four weeks, -17.0% over 12 weeks, and 14.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W6.0%
4W-0.4%
12W-17.0%
26W-24.0%
52W14.3%
Active trend streak0 weeks
Active weeks in one year28
Trend breadth53.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.39Latest activity-pressure read.
Pressure change7.2%Four-week change in activity pressure.
Leadership-24.98Latest relative-leadership reading.
RS change37.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

A published fundamentals and factor snapshot is not available for this company.

Open full factor analysis

No published fundamental snapshot is available for this company.

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 4 relevant articles.

0 positive · 3 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-35.2%Distance below the 52-week high.
13-week volatility4.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+12.2%Week of 20 Feb.
Worst week-10.8%Week of 6 Mar.
Latest week+6.0%Week of 7 Aug.

Shape of recent returns

Strong gains6
Modest gains3
Flat weeks0
Modest losses11
Sharp losses6
Recent vol4.8%13-week weekly-return volatility.
Base vol4.9%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew4.1% / -3.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis15/100

Latest 12-week confirmation: trend 1/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.23; No reversal markers Factors50/100

No published factor snapshot is available yet.

 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 4 relevant articles.

JW Pharmaceutical Q2 Operating Profit Jumps 33% on Prescription Drug Sales Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202624,900 KRW6.0%29,266 KRW27,197 KRW-1.39-24.98133.7KOff
31 Jul 202623,500 KRW-2.7%29,329 KRW27,295 KRW-1.40-33.49193.4KOff
24 Jul 202624,150 KRW-0.4%29,387 KRW27,362 KRW-1.43-33.45150.5KOff
17 Jul 202624,250 KRW-3.0%29,454 KRW27,432 KRW-1.47-35.22138.7KOff
10 Jul 202625,000 KRW-3.3%29,564 KRW27,510 KRW-1.50-39.85198.9KOff
3 Jul 202625,850 KRW7.3%29,617 KRW27,552 KRW-1.58-43.2555.0KOff
26 Jun 202624,100 KRW-9.7%29,604 KRW27,529 KRW-1.59-49.8283.0KOff
19 Jun 202626,700 KRW-1.3%29,651 KRW27,513 KRW-1.50-49.0875.8KOff
12 Jun 202627,050 KRW4.0%29,580 KRW27,481 KRW-1.32-43.3651.8KOff
5 Jun 202626,000 KRW-6.5%29,494 KRW27,445 KRW-1.11-46.6155.0KOff
29 May 202627,800 KRW-7.2%29,421 KRW27,415 KRW-0.97-45.88246.3KOff
22 May 202629,950 KRW-0.2%29,261 KRW27,375 KRW-0.84-38.03327.5KOn
15 May 202630,000 KRW-1.5%29,008 KRW27,324 KRW-0.74-35.89490.7KOn
8 May 202630,450 KRW-2.4%28,723 KRW27,278 KRW-0.71-35.78226.0KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context